Drug intelligence / Profile preview

Mac48

Development stage: Unknown
Lead developer: European Collection of Animal Cell Cultures
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Injection

Overview

Mac48 is a rat IgG2a monoclonal antibody that specifically targets phytochrome. It is utilized as a control antibody in preclinical research, particularly in studies involving pancreatic ductal adenocarcinoma models, to distinguish the effects of active therapeutic agents from non-specific antibody interactions. It is not intended as a therapeutic agent for the disease being studied.

Beyond the preview

Go deeper on Mac48.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mac48.

Explore the full profile